引子 最近有个有趣的现象：美联储降息预期越来越强，华尔街大佬们的观点却越来越分裂。这让我想起大学时教授说过的一句话："当专家们意见一致时，往往 是最危险的时候。"现在这种分歧反而让我觉得市场更真实了。 一、降息预期的迷雾与真相 最近美国经济数据确实给了市场一些惊喜。7月CPI环比0.2%，同比2.7%，都比预期要好。这直接导致市场对9月降息的预期飙升到93.4%。但有趣的是，华 尔街大佬们对降息幅度的预测却五花八门： 这种分歧让我想起2024年二季度那场闹剧。当时外资机构一边公开宣称"从不碰题材股"，一边却在疯狂买入重组概念股。要不是后来报表披露，谁能想到这 些"正人君子"背地里玩得这么花？ | 序号 | | ■ 股票代码 | 股票简称 | 现价(元) | 涨跌幅(%) | 区间涨跌幅:前复权(%) 2 | 机构持股数量明细(股) ? | 机构持股比例明细(%) ? | 机构持股市值明细(元)(2 | 持 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 2024.10.08-2024.10. ...

ST香雪（300147.SZ）8月14日在投资者互动平台表示，截至回复日，公司尚未收到中国证监会广东监 管局出具的《行政处罚决定书》。 每经AI快讯，有投资者在投资者互动平台提问：请问目前处罚申述进展如何？ （文章来源：每日经济新闻） ...

人民财讯8月13日电，企查查APP显示，近日，北京杜德生物科技有限公司成立，注册资本1000万元， 经营范围包含：第二类医疗器械销售；人体基因诊断与治疗技术开发；工程和技术研究和试验发展；生 物化工产品技术研发等。企查查股权穿透显示，该公司由广州杜德生物科技有限公司等共同持股，后者 大股东为ST香雪（300147）。 ...

Group 1 - The stock price of ST Xiangxue (300147) closed at 7.68 yuan on August 11, 2025, down 1.29% with a turnover rate of 2.05% and a trading volume of 134,500 hands, amounting to 103 million yuan [1] - The latest financial report for ST Xiangxue shows total operating revenue of 421 million yuan for Q1 2025, a year-on-year decrease of 25.99%, and a net profit attributable to shareholders of 87.73 million yuan, down 146.03% year-on-year [1] - The company has a current ratio of 0.277, a quick ratio of 0.223, and a debt-to-asset ratio of 81.75% [1] Group 2 - ST Xiangxue has made investments in 40 enterprises and participated in 2,157 bidding projects [2] - The company holds 244 trademark registrations and 165 patent registrations, along with 251 administrative licenses [2]

Group 1 - The recent U.S. non-farm employment data for July showed a significant miss in job additions, with the unemployment rate rising and previous months' data being revised downwards, raising concerns about the economic outlook [1][10]. - There is a growing divide within the Federal Reserve, with two officials voting in favor of interest rate cuts, a rare occurrence in the last 30 years, and market expectations for a September rate cut soaring to 93.6% [5][10]. - The market's perception of the weak employment data may be misleading, as it could indicate underlying shifts in institutional trading behavior, suggesting that institutions are positioning themselves ahead of potential market movements [9][10]. Group 2 - The article emphasizes the importance of focusing on actual trading behaviors rather than expert opinions, as institutional actions are more indicative of market trends [3][10]. - A quantitative tool is highlighted as essential for investors to discern market truths, allowing them to analyze trading behaviors and make informed decisions [8][9]. - The advice for ordinary investors includes maintaining independent thinking, filtering out noise, and utilizing quantitative tools to establish objective judgment standards [10][12].

Core Viewpoint - The company emphasizes the clinical value and market potential of its new drug TAEST16001 and is actively advancing the preparatory phase of confirmatory clinical trials [2]. Group 1 - The company is committed to keeping investors informed about the clinical progress of TAEST16001 and the status of its pre-restructuring efforts [2]. - The company plans to disclose updates regarding the new drug development and pre-restructuring progress in accordance with information disclosure regulations [2]. - Investors are encouraged to pay attention to the company's announcements for further details [2].

Core Viewpoint - The company confirmed that the clinical trial protocol for TAEST16001 includes clear standards for tumor antigen expression detection in target patients, but does not utilize organoid models for patient screening or efficacy validation [1] Group 1 - The clinical trial for TAEST16001 is a TCR-T cell therapy targeting tumor antigens [1] - The company has established specific criteria for detecting tumor antigen expression in patients during the Phase II clinical trial [1] - No organoid models or similar technologies are employed for patient selection or efficacy validation in the related studies [1]

Group 1 - The Anhui Provincial Drug Supervision Administration announced that a product from Bozhou Huqiao Pharmaceutical Co., Ltd. (a subsidiary of Guangzhou Xiangxue Pharmaceutical Co., Ltd.) failed to meet quality standards, specifically regarding its characteristics [1][2] - The announcement revealed that a total of 15 varieties and 16 batches of drugs were found non-compliant with standards, including issues related to characteristics, total ash, dissolution rate, moisture, weight variation, and identification [1] - The specific product in question, Winter Melon Seed, was sampled from Susong County Traditional Chinese Medicine Hospital, with the batch number 1901070142, and was tested against the Anhui Province Chinese Medicine Decoction Pieces Processing Specification 2015 edition [1][3] Group 2 - Huqiao Pharmaceutical was established on December 21, 2010, and is primarily engaged in the production and sale of traditional Chinese medicine pieces, including toxic pieces, as well as other food products [2] - Xiangxue Pharmaceutical holds a 70% stake in Huqiao Pharmaceutical and has been recognized as a leading enterprise in the modernization of traditional Chinese medicine, focusing on various health-related sectors [2]

Core Viewpoint - The antiviral oral liquid market is experiencing significant growth driven by the rising incidence of viral diseases and increasing health awareness among consumers, with a projected market size increase from 1.1 billion yuan in 2020 to 1.469 billion yuan in 2024, reflecting a compound annual growth rate of 7.5% [1][12]. Industry Overview - Antiviral oral liquids are common traditional Chinese medicine formulations, primarily composed of ingredients like Banlangen, Shigao, and Lugen, used for treating viral infections such as influenza and respiratory infections [3][5]. - The industry has evolved since the 1980s, transitioning from basic herbal formulations to more sophisticated products due to technological advancements, leading to improved efficacy and safety [5]. Market Dynamics - The demand for antiviral oral liquids is increasing due to the high prevalence of viral diseases and an aging population, alongside a shift in consumer perception of these products as essential for daily health protection [1][12]. - The rise of e-commerce platforms has further facilitated market growth by providing convenient access to these products [1][12]. Industry Chain - The industry chain consists of upstream raw material cultivation, production equipment, and packaging materials; midstream involves the manufacturing of antiviral oral liquids; and downstream includes sales through hospitals, pharmacies, clinics, and e-commerce platforms [8]. Competitive Landscape - The market is becoming increasingly competitive with numerous companies entering the field, necessitating continuous innovation and marketing efforts to stand out [13]. - Key players in the industry include ST Xiangxue, China Resources Sanjiu, Kangyuan Pharmaceutical, and others, each with unique product offerings and market strategies [1][13]. Development Trends - There is significant growth potential in the central and rural markets, where the penetration of antiviral oral liquids is currently low due to insufficient medical resources [21]. - Future innovations in nanotechnology and targeted drug delivery systems are expected to enhance product efficacy and reduce side effects, driving further advancements in the industry [22]. - The market is likely to see increased concentration as leading companies leverage technology and brand development to capture larger market shares, while new entrants may adopt innovative strategies to compete [23].

证券代码:300147 证券简称:ST 香雪 公告编号:2025—037 广州市香雪制药股份有限公司 关于董事会、监事会延期换届选举的公告 特此公告。 广州市香雪制药股份有限公司董事会 2025 年 7 月 25 日 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）第九届董事会、监事会 任期于近日届满。根据《中华人民共和国公司法》《上市公司章程指引》及《关 于新<公司法>配套制度规则实施相关过渡安排》等法律法规、规范性文件的要求， 公司拟修订《公司章程》及相关制度，并进行换届选举。目前，公司换届选举工 作尚在筹备中，为保证公司董事会、监事会工作的连续性和稳定性，公司第九届 董事会、监事会将延期换届，本届董事会各专门委员会、高级管理人员的任期也 将相应顺延。 在换届选举工作完成前，公司第九届董事会和监事会全体成员、董事会各专 门委员会成员及高级管理人员将按照相关法律、法规和《公司章程》的规定，继 续履行相应的职责和义务。 公司董事会、监事会延期换届不会影响公司的正常运营。公司将积极推进相 关换届选举工作，并及时履 ...